United States Patent 9,079,912: Scope of Claims and U.S. Patent Landscape for the JAK1/JAK2 Method
What do the claims cover at the compound and method level?
US Drug Patent 9,079,912 is directed to methods that inhibit JAK1 and/or JAK2 by administering a single defined chemical entity.
Core claimed compound (recited in independent method claims)
The asserted compound in Claims 1 and 3 is:
- 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
- or a pharmaceutically acceptable salt of that compound
The patent also explicitly covers a stereochemically defined embodiment:
- (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
- or salts of the (3R) form
Independent claim claim-basis
Two independent method frames appear:
- Inhibition of JAK1 and/or JAK2 (Claim 1)
- Blocking signal transduction at the JAK1 and/or JAK2 level (Claim 3)
Both are implemented through the same act: administering an effective amount of the same defined compound (or a salt).
How broad is the claim scope on mechanism and target coverage?
Target scope: JAK1 and/or JAK2
The phrasing “JAK1 and/or JAK2” covers multiple biological scenarios under the same method claims:
- JAK1 inhibition alone
- JAK2 inhibition alone
- dual JAK1/JAK2 inhibition
This matters because a competitor only needs to meet the claim’s functional requirement for the target set as written.
Mechanism framing: inhibition vs. signal transduction blockade
Claim 1 is a functional inhibition statement. Claim 3 is a functional signal transduction statement. These are distinct claim characterizations but they are tethered to the same administration step and same compound.
Practical effect:
- A formulation or dosing regimen that inhibits JAK1/JAK2 will likely read on both claim types if the claimed biological effect is satisfied.
- A formulation could potentially dispute one wording (signal transduction language) while conceding inhibition; the use of both frames reduces this design-around surface.
What is claimed on stereochemistry?
The patent’s dependent claims lock in a specific stereoisomer:
- Claims 2 and 5 restrict to (3R) configuration
- Claims 4 and 6 restrict to (3R) configuration in the “signal transduction” variant
Impact on competition
The existence of both generic (compound as written) and (3R) dependent claims creates an exploitable structure for competitors:
- If a competitor markets a different stereoisomer (or a racemate) and argues it is not “the compound” as recited, the independent claims become the central battleground.
- The independent claim recitation is not explicitly limited to (3R). It recites the compound name without specifying the “3R” designation in Claims 1 and 3.
From a strict claim-construction standpoint, that means the stereochemistry question will turn on how the compound is defined in the patent’s intrinsic record (name interpretation, structural formula, examples). Based on the claim text alone, Claims 1 and 3 are not textually limited to (3R), while the dependent claims are.
What is not claimed (and thus the immediate boundary of scope)?
Within the claim excerpts provided, the following are not limited in the claim text:
- Disease/indication: there is no explicit indication term in the method claims as provided (only “a patient in need thereof”).
- Dosage form: no formulation limitation appears in the claim text shown.
- Route of administration: the claims say “administering” without specifying route.
- Dose amount: the claims use “effective amount” without numeric ranges.
- Population characteristics: no demographic restrictions appear.
This combination usually expands practical enforcement reach to any therapeutic context where the accused product is used in a patient “in need thereof” for JAK1/JAK2 inhibition, unless other claim language elsewhere in the patent limits this (not provided here).
Claim-by-claim breakdown (what each adds)
| Claim |
Method framing |
Compound scope in claim text |
Additional limitation vs prior |
| 1 |
Inhibiting JAK1 and/or JAK2 |
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or salts |
Independent baseline |
| 2 |
Inhibiting JAK1 and/or JAK2 |
(3R) stereoisomer or salts |
Adds stereochemistry |
| 3 |
Blocking signal transduction at JAK1 and/or JAK2 level |
Same compound or salts |
Adds signal transduction framing |
| 4 |
Blocking signal transduction at JAK1 and/or JAK2 level |
(3R) stereoisomer or salts |
Adds stereochemistry to Claim 3 |
| 5 |
Inhibiting JAK1 and/or JAK2 |
(3R) stereoisomer (no “salts” text shown in the excerpt) |
Adds stereochemistry; excludes explicit salt language in the excerpt |
| 6 |
Blocking signal transduction |
(3R) stereoisomer (no “salts” text shown in the excerpt) |
Adds stereochemistry; excludes explicit salt language in the excerpt |
Note on salt coverage
Claims 1-4 explicitly include “or a pharmaceutically acceptable salt thereof” in your excerpt. Claims 5-6, as provided, recite the (3R) compound without the salt phrase. If this is verbatim from the record, Claims 5-6 may narrow to the free base entity (or rely on claim interpretation that salts still fall under “compound”). Enforcement strategy should treat Claims 1-4 as the cleaner salt-inclusion hooks.
How strong is the infringement hook for method-of-use products?
The claims are administration methods tied to a specific small molecule. That means infringement typically depends on whether the accused product:
- contains the recited compound (or a salt) as administered, and
- is used to inhibit JAK1 and/or JAK2 in the patient, or
- is used to block signal transduction at that level, and
- achieves an “effective amount.”
Because the claims do not recite an indication, enforcement can focus on therapeutic use that matches the JAK1/JAK2 functional outcome. The more clinically standard the JAK1/JAK2 mechanism is for the accused drug’s use in practice, the narrower the competitor’s practical defenses.
Where does this sit inside a typical U.S. JAK inhibitor patent landscape?
US JAK inhibitor families in the U.S. commonly cluster in three layers:
- Compound patents (composition of matter): cover the chemical entity itself.
- Method-of-use patents (medical treatment claims): cover therapeutic administration for a mechanism or disease.
- Combination and formulation patents: cover co-therapies and dosage forms.
US 9,079,912 is a method-of-use patent. That placement matters because it usually overlaps with:
- earlier or concurrent composition-of-matter coverage on the same active,
- later-life cycle method claims that narrow into specific stereochemistry, signal transduction language, or patient subgroups.
Practical landscape positioning for enforcement
Because this patent’s claims do not appear to be indication-limited in the excerpt, it can act as a broad mechanism umbrella for the defined compound across multiple JAK1/JAK2 uses where “patient in need thereof” is satisfied. It is structurally different from an indication-specific claim that requires the patentee to prove use for a named disease.
Potential claim construction battlegrounds (based on the claim text)
Even without the full specification, the claim language creates predictable disputes:
1) Does an accused product “administer” the same compound?
If a competitor uses a prodrug, metabolite, or alternative salt form, the literal infringement turns on whether the administered entity matches the claimed chemical structure or salt. Your excerpt’s focus on “the compound … or salts” implies that not all structurally related prodrugs will qualify.
2) Is the biological effect “inhibiting JAK1 and/or JAK2” or “blocking signal transduction” satisfied?
These are functional requirements. Competitors usually attack whether their product actually produces the claimed functional effect in the accused context, often by PK/PD profiling, target selectivity, or insufficient exposure at labeled doses.
3) Does the independent claim reach non-(3R) stereoisomers?
The independent claims do not textually limit to “(3R).” If the compound name in the patent record corresponds only to the (3R) form, then the stereochemistry restriction may still apply implicitly. If the name covers both stereochemical variants, then Claims 1 and 3 become broader than Claims 2/4/5/6.
Business implications: how the claims map to design-around strategies
For competitors seeking to avoid infringement while targeting JAK1/JAK2:
- Non-matching compound: changing the core structure is the cleanest route, since the claims are pinned to a specific chemical name.
- Alternative delivery: a change to route alone does not avoid an administration-based claim if the same compound is still administered.
- Stereochemical change: if the independent claims are interpreted to cover the general compound regardless of stereochemistry, switching away from (3R) is riskier. If the intrinsic record ties the compound name to (3R), then stereochemical change can be more effective, but the dependent claims suggest the patent anticipates at least a meaningful (3R) value proposition.
- Use context: because “patient in need thereof” is not indication-limited in the excerpt, narrowing by indication is weaker than in indication-specific patents, unless other limitations exist elsewhere in the document.
Key Takeaways
- US 9,079,912 claims methods of JAK1 and/or JAK2 inhibition and JAK1/JAK2 signal transduction blockade via administration of a single defined compound (or salts).
- The independent claims (1 and 3) are not textually limited to (3R), while dependent claims (2, 4, 5, 6) are.
- The claims are broad on indication, dose, route, and patient subtype as reflected in the excerpt, making enforcement likely to track therapeutic use where the JAK1/JAK2 functional outcome is achieved.
- Competitive design-around is most credible through non-matching chemistry; stereochemistry or use-context arguments depend on how the patent’s intrinsic record defines the compound name.
FAQs
-
Is this patent about a specific drug for a named disease?
The provided claims are mechanism-based and do not recite a specific indication, only “a patient in need thereof.”
-
Does the patent cover both JAK1 and JAK2?
Yes. The claim language covers “JAK1 and/or JAK2,” allowing inhibition of either target or both.
-
Are salts covered?
Claims 1-4 include “pharmaceutically acceptable salt thereof” in the excerpt. Claims 5-6, as provided, recite the (3R) compound without the salt phrase.
-
What is the role of (3R) stereochemistry in the claims?
Dependent claims add a (3R) limitation. The independent claims recite the compound without an explicit (3R) restriction in the excerpt.
-
Can a competitor avoid infringement by changing route or dosing form?
Route and dosage form are not limited in the excerpt. Avoidance would typically require avoiding the claimed compound (or qualifying salt) and/or avoiding the claimed JAK1/JAK2 functional effect.
Sources (APA)
[1] United States Patent No. 9,079,912 (claim text as provided by the user).
